Request Demo
Last update 31 May 2025
Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharmaceutical Co. Ltd.)
Last update 31 May 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms F182112 |
Target |
Action inhibitors, stimulants |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharmaceutical Co. Ltd.)NCT04984434
A First-in-human, Open-label, Multiple Center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients With Relapsed or Refractory Multiple Myeloma.
CTR20250778
评价F182112联合不同给药方案治疗复发或难治性多发性骨髓瘤患者的有效性和安全性的开放、多中心II期临床研究
[Translation] An open, multicenter phase II clinical study to evaluate the efficacy and safety of F182112 combined with different dosing regimens in the treatment of patients with relapsed or refractory multiple myeloma
100 Clinical Results associated with Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharmaceutical Co. Ltd.)
Login to view more data
100 Translational Medicine associated with Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharmaceutical Co. Ltd.)
Login to view more data
100 Patents (Medical) associated with Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharmaceutical Co. Ltd.)
Login to view more data
1
Literatures (Medical) associated with Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharmaceutical Co. Ltd.)Journal of hematology & oncology
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Letter
Author: Song, Yongping ; Ren, Quan ; Zhao, Juanjuan ; Liu, Xinyuan ; Guo, Xiangqian
Abstract:
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.
100 Deals associated with Recombinant humanized anti-BCMA/CD3 bispecific antibody(Shandong New Time Pharmaceutical Co. Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Myeloma | Phase 2 | China | 23 Apr 2025 | |
| Refractory Multiple Myeloma | Phase 1 | China | 30 Jul 2021 | |
| Relapse multiple myeloma | Phase 1 | China | 30 Jul 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 22 | mhvdpugvwd(rplatzrpdv) = dibsatwcjj qsoguoelzl (xkycpvngvt ) View more | - | 09 Dec 2023 | |||
Phase 1 | 16 | grannspwsf(zghojkoqlr) = ofqkupmers vzzjoeilsu (nzvqlajlrn ) View more | Positive | 26 May 2023 | |||
(pts treated with ≥ 10 μg/kg F182112) | fbuugwszak(ipouqnwzru) = dicnhuhbkd conhbkvmkv (xpokutevux ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free